Cost-effectiveness of palivizumab prophylaxis for respiratory syncytial virus (RSV) : a systematic review.: HP40-320/2022E-PDF
"Palivizumab (PVZ) prophylaxis is used as passive immunization for respiratory syncytial virus (RSV). However, due to its high acquisition costs, the value of this intervention is unclear. The objective of this study was to systematically review the cost-effectiveness of PVZ prophylaxis compared to no prophylaxis in infants under 24 months of age"--Executive summary, page 3.
Permanent link to this Catalogue record:
publications.gc.ca/pub?id=9.914232&sl=0
| Department/Agency | Public Health Agency of Canada, issuing body. |
|---|---|
| Title | Cost-effectiveness of palivizumab prophylaxis for respiratory syncytial virus (RSV) : a systematic review. |
| Publication type | Monograph |
| Language | [English] |
| Other language editions | [French] |
| Format | Electronic |
| Electronic document | |
| Note(s) | Cover title. "Publication date: January 2023." At head of title: An Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI). Issued also in French under title: Rapport coût-efficacité de la prophylaxie par palivizumab pour le virus respiratoire syncytial (VRS) : un examen systématique. Includes bibliographical references (pages 15-18). |
| Publishing information | [Ottawa] : Public Health Agency of Canada = Agence de la santé publique du Canada, 2023. ©2023 |
| Description | 1 online resource (41 pages) : graphs |
| ISBN | 9780660449364 |
| Catalogue number |
|
| Departmental catalogue number | 220361 |
| Subject terms | Palivizumab -- Canada -- Cost effectiveness. Respiratory syncytial virus -- Canada. Infants -- Diseases -- Canada. |
Request alternate formats
To request an alternate format of a publication, complete the Government of Canada Publications email form. Use the form’s “question or comment” field to specify the requested publication.- Date modified: